Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk

Molecular Therapy

Volumn 1, Issue 1, 2000, Pages 56-62

  Morris, John C ^a   Wildner, Oliver ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gene therapy; replication competent adenovirus; HSV 1 tk ganciclovir; head and neck cancer

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; PROTEIN P53; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CYTOPATHOGENIC EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HERPES SIMPLEX VIRUS 1; HUMAN; METABOLISM; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; THYMIDINE KINASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033643594     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.1999.0014     Document Type: Article

References (42)

1. Babiss L. E., Ginsberg H. S., Darnell J. E. Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell Biol. 5:1985;2552-2558.
2. Barker D. D., Berk A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 156:1987;107-121.
3. Bett A. J., Haddara W., Prevec L., Graham F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA. 91:1994;8802-8806.
4. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
5. Bonsing B. A., Corver W. E., Gorsira M. C., van Vliet M., Oud P. S., Cornelisse C. J., Fleuren G. J. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry. 28:1997;11-24.
6. Bridge E., Ketner G. Interaction of adenoviral E4 and E1b products in late gene expression. Virology. 174:1990;345-353.
7. Chen S. H., Shine H. D., Goodman J. C., Grossman R. G., Woo S. L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 91:1994;3054-3057.
8. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
9. Dethlefsen L. A., Prewitt J. M., Mendelsohn M. L. Analysis of tumor growth curves. J. Natl. Cancer Inst. 40:1968;389-405.
10. Freeman S. M., Abboud C. N., Whartenby K. A., Packman C. H., Koeplin D. S., Moolten F. L., Abraham G. N. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
11. Freytag S. O., Rogulski K. R., Paielli D. L., Gilbert J. D., Kim J. H. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9:1998;1323-1333.
12. Ghattas I. R., Sanes J. R., Majors J. E. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell Biol. 11:1991;5848-5859.
13. Goodrum F. D., Ornelles D. A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71:1997;548-561.
14. Goodrum F. D., Ornelles D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
15. Graham F. L., Prevec L. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:1995;207-220.
16. Halbert D. N., Cutt J. R., Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Virol. 56:1985;250-257.
17. Hall A. R., Dix B. R., O'Carroll S. J., Braithwaite A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1998;1068-1072.
18. Hall S. F., Groome P. A., Rothwell D., Dixon P. F. Using the TNM system to predict survival in squamous cell carcinoma of the head and neck. Anticancer Res. 18:1998;4777-4778.
19. Harada J. N., Berk A. J. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73:1999;5333-5344.
20. Haynes P., Lambert T. R., Mitchell I. D. Comparative in-vivo genotoxicity of antiviral nucleoside analogues: Penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat. Res. 369:1996;65-74.
21. Ilsley D. D., Lee S. H., Miller W. H., Kuchta R. D. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry. 34:1995;2504-2510.
22. Kim M. S., Li S. L., Bertolami C. N., Cherrick H. M., Park N. H. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res. 13:1993;1405-1413.
23. Kirn D., Hermiston T., McCormick F. ONYX-015: Clinical data are encouraging. Nat. Med. 4:1998;1341-1342.
24. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J. Clin. 49:1999;8-31.
25. Larson D. L., Lindberg R. D., Lane E., Goepfert H. Major complications of radiotherapy in cancer of the oral cavity and oropharynx. A 10 year retrospective study. Am. J. Surg. 146:1983;531-536.
26. Leppard K. N., Shenk T. The adenovirus E1B 55 kD protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J. 8:1989;2329-2336.
27. Miller W. H., Miller R. L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J. Biol. Chem. 255:1980;7204-7207.
28. Mittereder N., March K. L., Trapnell B. C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:1996;7498-7509.
29. Moolten F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281.
30. Morgan R. A., Couture L., Elroy-Stein O., Ragheb J., Moss B., Anderson W. F. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20:1992;1293-1299.
31. Okada T., Ramsey W. J., Munir J., Wildner O., Blaese R. M. Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex. Nucleic Acids Res. 26:1998;1947-1950.
32. Punwaney R., Brandwein M. S., Zhang D. Y., Urken M. L., Cheng R., Park C. S., Li H. B., Li X. Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: Investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck. 21:1999;21-29.
33. Reiss M., Brash D. E., Munoz-Antonia T., Simon J. A., Ziegler A., Vellucci V. F., Zhou Z. L. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol. Res. 4:1992;349-357.
34. Rothmann T., Hengstermann A., Whitaker N. J., Scheffner M., zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
35. Scheffner M., Huibregtse J. M., Vierstra R. D., Howley P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
36. Smith R. R., Huebner R. J., Rowe W. P., Schatten W. E., Thomas L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9:1956;1211-1218.
37. Thust R., Schacke M., Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res. 31:1996;105-113.
38. Turnell A. S., Grand R. J., Gallimore P. H. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:1999;2074-2083.
39. Vojtesek B., Bartek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151:1992;237-244.
40. Wildner O., Blaese R. M., Morris J. C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV-tk. Cancer Res. 59:1999;410-413.
41. Wildner O., Morris J. C., Vahanian N. N., Ford H. Jr., Ramsey W. J., Blaese R. M. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6:1999;57-62.
42. Yew P. R., Kao C. C., Berk A. J. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology. 179:1990;795-805.